Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update
APVO436 Phase 1b Trial for Acute Myeloid Leukemia Adds New SiteComplete Remission Patient to Advance to TransplantSEATTLE, WA / ACCESSWIRE...